Insulet (PODD) has disclosed a new risk, in the Natural and Human Disruptions category.
Insulet faces significant business and financial risks from the potential emergence of another global pandemic or new variants of COVID-19. Such events could disrupt clinical trials and delay FDA product approvals, as seen with Omnipod 5 during the COVID-19 pandemic. A shift to remote work has heightened cybersecurity threats, posing risks to IT systems and data integrity. Furthermore, pandemics could severely impact Insulet’s supply chain, affecting manufacturing, distribution, and third-party services critical to product sterilization and delivery.
The average PODD stock price target is $321.50, implying 13.68% upside potential.
To learn more about Insulet’s risk factors, click here.